Health Condition 1: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx
Conditions
Interventions
Intervention1: Group-TDB: Transdermal Buprenorphine patch dose of 10 microgram will be applied on skin on post operative day 6 and followed on 1st , 2nd, 4th, 6th and 8th week post operatively for to
Sponsors
University College of Medical Sciences
Eligibility
Inclusion criteria
Inclusion criteria: Operated case of Head and Neck cancer, managed with Standard Postoperative Pain Management Protocol, for initial five days of post-operative period with Pain intensity >= 4/10 of Numerical Rating Scale-pain scale on post-operative day 6
Exclusion criteria
Exclusion criteria: •Evidence of other sources of pain that may confound the diagnosis •Recent history of any other surgery other than that for HNC •Patients with past H/o MI, DM, pancreatitis and vasculitis. •Patients with evidence of hepatic or renal impairment. •Patients having allergy/intolerance to oral/parenteral/transdermal patches.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients achieving NRS-pain score â?¤3/10Timepoint: Proportion of patients achieving NRS-pain score â?¤3/10 | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of GPE ScoreTimepoint: At 1st, 2nd, 4th, 6th and 8th week post patch application;Comparison of NPSI ScoreTimepoint: At 1st, 2nd, 4th, 6th and 8th week post patch application;Comparison of PDI ScoreTimepoint: At 1st, 2nd, 4th, 6th and 8th week post patch application;Comparison of PDQTimepoint: At 1st, 2nd, 4th, 6th and 8th week post patch application;Comparison of SF-12 scoreTimepoint: At 1st, 2nd, 4th, 6th and 8th week post patch application;Modulation in mRNA expressions of IL-6 and mTORC1 genesTimepoint: Pre-treatment and at the end of 12th week post treatment | — |
Countries
India
Contacts
Public ContactDr Geetanjali T Chilkoti
University College of Medical Sciences and GTB
Outcome results
None listed